BioCentury | Feb 6, 2020
Deals

Beyond Keytruda: How Merck envisions innovation and growth after a spinout

...and CEO of Humacyte Inc. as well as EVP and president of global pharmaceuticals at Schering-Plough...
BioCentury | Dec 12, 2018
Company News

Management tracks: Merck creates new commercial roles to follow Schechter's exit

...has been president of Global Human Health since 2010. He led the pharma's integration with Schering-Plough Corp....
BioCentury | Feb 16, 2017
Company News

NexImmune deal

...company also named a new board led by Chairman Robert Spiegel, a former CMO at Schering-Plough Corp....
BioCentury | Feb 14, 2017
Financial News

Barer among investors acquiring NexImmune

...company also named a new board led by chairman Robert Spiegel, a former CMO at Schering-Plough Corp....
...the investment, but are no longer represented. Jaime De Leon AstraZeneca plc Celgene Corp. MedImmune LLC Medtronic plc NexImmune Inc. Roivant Sciences Ltd. Schering-Plough Corp. Teva...
BioCentury | Jul 11, 2016
Finance

Advising Israel

...venture advisors Robert Spiegel and Ed Saltzman are joining Vidac's board. Spiegel was CMO of Schering-Plough Corp....
BioCentury | Jun 9, 2016
Strategy

Sanofi's post-reconstruction era

...of Texas MD Anderson Cancer Center , DNAX Institute of Cellular and Molecular Biology, and Schering-Plough Corp....
BioCentury | Jun 8, 2015
Emerging Company Profile

Financing innovation in China

...at Yabao, spent nearly 20 years in the U.S. as a research fellow at the Schering-Plough...
BioCentury | Feb 5, 2015
Distillery Therapeutics

Therapeutics: Viral protein 1 (VP1)

...determining their infectivity in the presence of pleconaril. As late as 2006, ViroPharma Inc. and Schering-Plough Corp....
BioCentury | Feb 2, 2015
Politics, Policy & Law

Dr. Califf goes to Washington

...Co. Eli Lilly and Co. Johnson & Johnson Merck & Co. Inc. Novartis AG Roche Schering-Plough Corp....
BioCentury | Apr 17, 2014
Cover Story

Contaminating cancer genomes

...determine the target of a 15-year-old compound that had been synthesized by Schering-Plough Corp. , SCH51344. Schering-Plough...
Items per page:
1 - 10 of 2220
BioCentury | Feb 6, 2020
Deals

Beyond Keytruda: How Merck envisions innovation and growth after a spinout

...and CEO of Humacyte Inc. as well as EVP and president of global pharmaceuticals at Schering-Plough...
BioCentury | Dec 12, 2018
Company News

Management tracks: Merck creates new commercial roles to follow Schechter's exit

...has been president of Global Human Health since 2010. He led the pharma's integration with Schering-Plough Corp....
BioCentury | Feb 16, 2017
Company News

NexImmune deal

...company also named a new board led by Chairman Robert Spiegel, a former CMO at Schering-Plough Corp....
BioCentury | Feb 14, 2017
Financial News

Barer among investors acquiring NexImmune

...company also named a new board led by chairman Robert Spiegel, a former CMO at Schering-Plough Corp....
...the investment, but are no longer represented. Jaime De Leon AstraZeneca plc Celgene Corp. MedImmune LLC Medtronic plc NexImmune Inc. Roivant Sciences Ltd. Schering-Plough Corp. Teva...
BioCentury | Jul 11, 2016
Finance

Advising Israel

...venture advisors Robert Spiegel and Ed Saltzman are joining Vidac's board. Spiegel was CMO of Schering-Plough Corp....
BioCentury | Jun 9, 2016
Strategy

Sanofi's post-reconstruction era

...of Texas MD Anderson Cancer Center , DNAX Institute of Cellular and Molecular Biology, and Schering-Plough Corp....
BioCentury | Jun 8, 2015
Emerging Company Profile

Financing innovation in China

...at Yabao, spent nearly 20 years in the U.S. as a research fellow at the Schering-Plough...
BioCentury | Feb 5, 2015
Distillery Therapeutics

Therapeutics: Viral protein 1 (VP1)

...determining their infectivity in the presence of pleconaril. As late as 2006, ViroPharma Inc. and Schering-Plough Corp....
BioCentury | Feb 2, 2015
Politics, Policy & Law

Dr. Califf goes to Washington

...Co. Eli Lilly and Co. Johnson & Johnson Merck & Co. Inc. Novartis AG Roche Schering-Plough Corp....
BioCentury | Apr 17, 2014
Cover Story

Contaminating cancer genomes

...determine the target of a 15-year-old compound that had been synthesized by Schering-Plough Corp. , SCH51344. Schering-Plough...
Items per page:
1 - 10 of 2220